Investigator/Firm Financial Ties May Trigger Heavier Scrutiny Of Data By FDA
Executive Summary
Disclosure of financial arrangements between a clinical investigator and study sponsor will lead to a more stringent product review at FDA, Office of Drug Evaluation I Associate Director-Regulatory Affairs Linda Carter told the Food & Drug Law Institute.